Lilly’s Emgality Approved to Treat Cluster Headaches

Lilly plans to present trial results at scientific meetings and publications this year and in 2016.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says one of its headache treatments has received approval from the U.S. Food and Drug Administration. Emgality is a treatment for episodic cluster headache in adults.

The treatment, which hit the market last year, allows patients to inject Emgality at home at the beginning of a cluster headache period, and then monthly until the end of a cluster period. Emgality was first approved by the FDA in September 2018 for the preventive treatment of migraine in adults.

"Episodic cluster headache can be devastating. The approval of Emgality for the treatment of episodic cluster headache is an important milestone as it provides a new treatment option, which has been long-awaited by those impacted by this disease," said Christi Shaw, president, Lilly Bio-Medicines, in a news release.